Abstract:Objective: To develop an in vitro model of Parkinson's disease (PD) with PD serum IgG and investigate the mechanism by which PD IgG (60 μg/ml) injures mesencephalic dopaminergic neurons. Methods: IgGs was purified from serum samples of patients with idiopathic Parkinson's disease and other neurological diseases (DC), and healthy people (NC) by using ferric ammonium sulfate precipitation, ion exchange chromatography and filtration dialysis. Rat mesencephalic cells were exposed to IgGs in presence or absence of complement. Cell viability was measured by MTT assay. The number and morphology of cells were determined by tyrosine hydroxylase (TH) and β-tubulin immunocytochemistry. Cell bioactivity was detected by [3H] DA and [3H] GABA uptake analyses. Also, the amount of some key cytotoxic factors was examined, including TNF-α and IL-1β (ELISA), NO (Griess method), and superoxide (cytochrome c method). Results: The number, morphology and bioactivity of rat embryo mesencephalic neuron-glia cells were not altered following exposure to PD IgG or complement respectively (P > 0.05). After the exposure to PD IgG together with complement, the number of TH (+) neurons and activity of DA uptake were significantly decreased from 1012.3 cpm to 670.5 cpm (P < 0.01), while total cell viability was not markedly altered (P > 0.05). Morphologically, the neurites of TH (+) neurons became fewer and shorter. In contrast, the number of β-tubulin(+) neurons and activity of GABA uptake did not change obviously (P > 0.05). For primary mesencephalic neuron-enriched cultures, the exposure to PD IgG did not result in significant changes in the number, morphology and activity of TH(+) neurons even in the presence of complement (P > 0.05). Also, no alternations in the number, morphology and activity of DA neurons were found following the exposure of primary mesencephalic neuron-glia to the IgGs from DC and NC, even in the presence of complement (P > 0.05). Finally, in sharp contrast to the lack of co-treatment of PD IgG and complement in stimulating the production of TNF-α, IL-1β and NO, PD IgG significantly stimulated the release of superoxide (4.65 nmol/106 cell) in the presence of complementas compared with the control (P < 0.005). CAT (50 U/ml) /SOD (50 U/ml) significantly reduced PD IgG-induced injury of TH(+) neurons (P < 0.01). However, pretreatment of neuron-glia cultures with neutralizing antibodies specific for rat TNF-α (50 μg/ml) or for IL-1β (10 μg/ml), or 1 mmol/L NG-nitro-L-arginine methyl ester did not afford any significant neuroprotection (P > 0.01). Conclusions: PD IgG might cause a relatively selective injury of mesencephalic dopaminergic neurons, which was mediated by complement, glia and superoxide, This suggests that immunity might be involved in the pathogenesis of Parkinson's disease.

Study on Lipopolysaccharide Injury of Dopaminergic Neurons and Its Relevant Mechanism

The Effects of NF-κB on Parkinson Disease Rat Model Induced by LPS

Effects of intraperitoneal injection of lipopolysaccharide-induced peripheral inflammation on dopamine neuron damage in rat midbrain

Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson’s Disease in C57BL/6 Mice

The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery

In Vivo Detection of Monoaminergic Degeneration in Lipopolysaccharide-Induced Rat Model of Parkinson's Disease Using 18F-FP-(+)-DTBZ (18F-AV-133) PET

IL‐1β/IL‐1R1 signaling induced by intranasal lipopolysaccharide infusion regulates alpha‐Synuclein pathology in the olfactory bulb, substantia nigra and striatum

Protective effects of endotoxin tolerance on peripheral lipopolysaccharide-induced neuroinflammation and dopaminergic neuronal injury

LPS Triggers Acute Neuroinflammation and Parkinsonism Involving NLRP3 Inflammasome Pathway and Mitochondrial CI Dysfunction in the Rat

Systemic Infusion of Naloxone Reduces Degeneration of Rat Substantia Nigral Dopaminergic Neurons Induced by Intranigral Injection of Lipopolysaccharide.

Degeneration of Dopaminergic Neurons and Changes of Inducible Nitric Oxide Synthase Induced by a Proteasome Inhibitor

Effects of L-dopa on Cells Expressing D2 Receptors and Level of Dopamine Transmitter in Hemiparkinsonian Rats

Systemic Inflammation Increases The Susceptibility To Levodopa-Induced Dyskinesia In 6-Ohda Lesioned Rats By Targeting The Nr2b-Medicated Pkc/Mek/Erk Pathway

Lipoic Acid Protects Dopaminergic Neurons in LPS-induced Parkinson's Disease Model.

Preliminary study on mechanism underlying toxicity of IgG from Parkinson's disease on mesencephalic dopaminergic cultures

The efficacy of systemic administration of lipopolysaccharide in modelling pre-motor Parkinson’s disease in C57BL/6 mice

The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson's Disease

Lipoic acid protects dopaminergic neurons in LPS-induced model of Parkinson’s disease

The Degeneration of Dopaminergic Neuron and Inclusion-Like Formation Induced by the Inhibitor of Proteasome

The Study on the Relationship Between Proteasome Function and Parkinson Disease

The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson’s Disease in Rats